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TUTORIAL
MatVPC: A User-Friendly MATLAB-Based Tool for the
Simulation and Evaluation of Systems Pharmacology
Models
K Biliouris1, M Lavielle2 and MN Trame1*
Quantitative systems pharmacology (QSP) models are progressively entering the arena of contemporary pharmacology. The
efficient implementation and evaluation of complex QSP models necessitates the development of flexible computational tools
that are built into QSP mainstream software. To this end, we present MatVPC, a versatile MATLAB-based tool that
accommodates QSP models of any complexity level. MatVPC executes Monte Carlo simulations as well as automatic
construction of visual predictive checks (VPCs) and quantified VPCs (QVPCs).
CPT Pharmacometrics Syst. Pharmacol. (2015) 4, 547–557; doi:10.1002/psp4.12011; published online on 22 August 2015.
VPC is a model diagnostic tool that facilitates the evaluation
of both the structural and the stochastic part of a model. It
is constructed by superimposing the observations over the
model simulations while accounting for both the interindivid-
ual variability as well as the residual variability.1 Once
underutilized,2 the VPC now is recognized as one of the
most valuable model diagnostics in pharmacological model
evaluation.3–5 Its superiority over comparable diagnostic
tools has been established6 and reflected by the fact that
regulatory agencies recommend it as one of the central
model diagnostics.7
The VPC has recently evolved and key features have
been added to its originally simple version.8–10 These fea-
tures aid in better visualizing the data and include but are
not limited to summary statistics and binning of the simu-
lated and observed data. Extensions to the VPC have also
been developed aiming for a highly objective model evalua-
tion. A VPC extension example includes QVPC, wherein
the distribution of the observations around the predicted
median trend is rigorously realized.11
To ease the VPC construction process, several practical
software products have been developed that automatically
generate comprehensive VPC plots, which are challenging
to generate otherwise. Such software products include
Monolix12 and Xpose-PsN (coupled with NONMEM),13,14
among others.15–17 Monolix carries out the simulations
and uses the outcome to generate the VPC plots,
whereas PsN uses NONMEM18 as the simulation platform
and performs the percentile calculations. Subsequently,
the latter are plotted using Xpose. The immense practical-
ity of these tools, however, comes with its set of short-
comings: (i) they inevitably carry out parameter estimation
of a model before constructing its VPC; (ii) they do not
offer extensions to the VPC; and (iii) generating VPCs of
high complexity datasets may be devious. These draw-
backs render these tools unattractive for constructing
VPCs of high complexity models or of models that have
already been built in different software and require no fur-
ther parameter estimation.
Recently, a growing body of literature has been demon-
strating the catalytic role of high complexity, systems-level
models in the pharmacology arena.19–27 Traditionally, the
so-called “QSP” models are not implemented in Monolix or
NONMEM but in surrogate software tools, such as MATLAB
or MATLAB-based software.8,28–37 VPC plots that are gen-
erated with these tools are generally not as comprehen-
sive31,38 lacking important features, such as confidence
intervals of simulation percentiles or data binning. As it was
previously discussed, VPCs that lack these features may
not be sufficiently informative.1,9,11
The progressive incorporation of QSP models in the
regulatory arena39 necessitates the development of flexi-
ble computational tools that are built into software com-
monly used for such models; these tools can be then
routinely utilized in evaluating and simulating QSP models.
To this end, we developed MatVPC: a flexible, user-
friendly MATLAB-based tool that carries out Monte Carlo
simulation as well as VPC construction of QSP models of
any complexity level. MatVPC accommodates any model,
independently of the software used for model develop-
ment, while offering the majority of options that compara-
ble tools list. Provided that certain features of a model
may not be readily visualized in a VPC,11 MatVPC grants
the additional option of constructing QVPC plots of the
available data.
MATVPC TUTORIAL
In this tool, the user simply inputs: (i) the model equations;
(ii) the model parameters; and (iii) the NONMEM-like data-
set with observations, and MatVPC outputs VPCs, QVPCs,
or Monte Carlo simulation plots at will. The inputted model
parameters here include macrokinetic or microkinetic con-
stants, initial conditions of ordinary differential equations
1Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, University of Florida, Orlando, Florida, USA; 2Inria Saclay, POPIX Team,
Saclay, France. *Correspondence: MN Trame (mtrame@cop.ufl.edu)
Received 27 April 2015; accepted 10 July 2015; published online on 22 August 2015. doi:10.1002/psp4.12011
Citation: CPT Pharmacometrics Syst. Pharmacol. (2015) 4, 547–557; doi:10.1002/psp4.12011
VC 2015 ASCPT All rights reserved
Table 1 Default values and accepted values included in MatVPC’s optional input interface
Options Default value Accepted input
No. of datasets 200 Scalar
Automatic binninga Yes Yes, no
Manual binningb No Yes, no
Bin edges [ ] Vector with as many scalars as the bin edges
No. of simulated timepointsc 100 Scalar
Run Monte Carlo simulationsd No Yes, no
ODE solvere ode23tb ode45, ode23, ode113, ode15s, ode23s, ode23t, ode23tb
Simulated time beyond observationsf 0 Scalar
Upper percentile limit of simulations 95 Scalar
Lower percentile limit of simulations 5 Scalar
Plot observationsg Yes Yes, no
Plot percentiles of observations Yes Yes, no
Upper percentile limit of observations 95 Scalar
Lower percentile limit of observations 5 Scalar
Plot QVPC Yes Yes, no
Replace negative and zero valuesh No Yes, no
Replacement value 0.001 Scalar
Graphical settings
Type of median curve in simulations – –, – –,:, –., o, 1, *, .,:, x, s, d, ^, v, >, <, p, h
Color of median curve in simulationsi Black Color name
Type of percentiles curve in simulations – – –, – –,:, –., o, 1, *, .,:, x, s, d, ^, v, >, <, p, h
Color of percentiles curve in simulationsi Black Color name
Color of median CI in simulationsi Deep pink Color name
Color of percentiles CI simulationsi Blue Color name
Color of observationsi Blue Color name
Size of observations 10 Scalar
Color of median curve in observationsi Red Color name
Color of percentiles curve in observationsi – – –, – –,:, –., o, 1, *, .,:, x, s, d, ^, v, >, <, p, h
Type of median curve in observations – –, – –,:, –., o, 1, *, .,:, x, s, d, ^, v, >, <, p, h
Type of percentiles curve in observations – – –, – –,:, –., o, 1, *, .,:, x, s, d, ^, v, >, <, p, h
Color of simulation median in QVPCi Red Color name
Color of observations above median in QVPCi Grey Color name
Color of observations below median in QVPCi Black Color name
Number of rows in figure 1 Scalar
Number of columns in figure 3 Scalar
Square shaped plots Yes Yes, no
Width of all curves 1 Scalar
Log-y scale No Yes, no
X-axis label Time Any alphabetic input
Y-axis label Observations/simulations Any alphabetic input
Transparency of CI shaded areas 0.5 Scalar
CI, Confidence Intervals; ODE, ordinary differential equation; QVPC, quantified visual predictive check.
aFor a detailed description of how the bin edges are selected, please refer to Ref. 9 and 40. Before the results of the automatic binning are accepted, a visual
inspection of the calculated bin edges should be done as, in extreme cases of data point distributions, the code might not generate optimal results.
bIn case “yes” is selected here, a vector with the bin edges should be defined in the following option.
cThis option allows modification of the number of equally spaced timepoints that are saved during the Monte Carlo simulations. The larger the numbers, the
slower the runtime.
dThis option requests Monte Carlo simulations can be selected in other options (see footnotes c and f).
eThe ODE solver should be carefully chosen based on the type of the model, in other words, whether the model is stiff or not.
fThis number represents the percentage of the entire simulation time that is simulated beyond the latest observation point. For instance, in case the user
desires to run a Monte Carlo simulation for an additional time equal to 20% of the entire profile, this number should be set equal to 0.2 (see Monte Carlo simu-
lations in model one).
gThis option allows the user to plot simulation results without plotting the observations. In case the user desires to simply plot Monte Carlo simulations of the
model, “no” should be selected.
hThis option should be exploited in case the user wants to avoid negative concentrations and associated plotting issues, for instance, when a logarithmic scale
is used. In case “yes” is selected here, the desired replacement value should be defined in the following option.
iThe color of the curves is defined by writing the name of any of the 139 available color names provided at http://www.w3.org/TR/css3-color/. Note that the first
letter should be capital.
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(ODEs) and variability terms; MatVPC allows for imple-
menting both interindividual variability and RUV, which can
be in the form of proportional, additive, or combined error.
The dataset should be provided in a comma-separated val-
ues format including, at a minimum, the following headers
in no particular order and in a case-insensitive manner: (i)
TIME; (ii) ID; (iii) CMT; (iv) DV (nonexistent DVs should be
represented by a dot); (v) EVID; (vi) AMT; and (vii) RATE
(only in the case of intravenous infusion dosing).
Once the user provides the aforementioned information,
they must insert in the command line: (i) the name of the
dataset; and (ii) the stratification variables, if any, as follows:
MatVPC (‘dataset.csv’, {‘stratification1’, ‘stratification2’}).
Common stratification variables include but are not limited
to arms of a trial (placebo and active control), routes of
administration, dose intervals, and, generally, covariates
affecting any model parameters.1 At present, MatVPC
accepts up to two stratification variables, whereas compart-
ment is a default stratification variable and MatVPC will
always stratify on it. It should be highlighted that MatVPC
treats each ODE as a “compartment,” however, it only con-
structs VPC plots for the compartments with available
observations. Once the information (i) and (ii) is provided,
the user is asked (iii) to input the name of the model, which
can be any alphanumeric value (e.g., Model1); and (iv) to
state whether they want to run simulations and construct
VPCs or to simply construct VPCs using previously saved
simulation results. Please note that the former option
requires the user to simply provide a desired name for the
model, unlike the MATLAB file ODEs, wherein the user pro-
vides the model equations. Option 4 is expected to be use-
ful in cases where simulations of a model have already
been carried out and the user wants to simply reconstruct
VPCs with modified characteristics, such as different color
lines or altered binning edges. Parenthetically, when this
option is exploited, the simulation-related parameters
should be set to the same values as in the original VPC
construction.
Upon providing all the above, a user-friendly interface
commences allowing the user to modify the default values
in a series of optional inputs. This input includes options
related to the methods (e.g., ODE solver to be used or
number of datasets to be simulated) as well as options that
determine the graphical settings (e.g., color and type of
Figure 1 Required input in MatVPC for model one. (a) Input in file “parameters.” In this file, the user inputs the values of the ODE
parameters, the values of the interindividual variability parameters, the proportional and additive part of the RUV, the initial conditions
of the ODEs and the volume size of each compartment. (b) Input in file “ODEs.” In this file, the user inputs the ODEs, along with
potential algebraic equations, describing the quantitative pharmacology model. In case of IV infusion dosing, an additional term should
be included in the model that accounts for the dosing (for an example see model two).
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plotting curves). Table 1 details the accepted optional input
along with the default values.
It is important to stress that, unlike analogous tools
that are traditionally used in pharmacometrics, MatVPC
constitutes an all-in-one package that integrates the
following:
1. It is publicly open (at https://sourceforge.net/projects/
matvpc/);
2. Constructs VPC plots of complex QSP models;
3. Offers automatic binning of the observed and simulated
data using a rigorous approach9,40;
4. Constructs QVPC plots of complex QSP models;
5. Performs Monte Carlo simulations of the model and plots
the results with any requested summary statistics;
6. Does not require prior implementation (e.g., parameter
estimation) of the model within MATLAB;
7. Endows the user with the option to perform post-
processing of the VPC, QVPC, or simulation plots.
In what follows, we implement three models with varying
characteristics to demonstrate the functionality of MatVPC.
These models include: (i) a linear three compartment phar-
macokinetic (PK) model with single oral and intravenous
(IV) bolus dosing; (ii) a nonlinear two compartment PK
model with multiple IV infusion dosing41; and (iii) a highly
nonlinear pharmacodynamic (PD) model that describes the
time-course of body weight.42 To validate the accuracy of
the presented VPCs, we directly compare them with VPCs
generated either by Xpose version 4 (coupled with PsN
version 4.2.0 and NONMEM version 7.2) or by Monolix ver-
sion 4.3.3.
Model one: three-compartment PK model with
oral and IV bolus dosing
The first model describes simulated data of a linear three-
compartment PK model with linear elimination from the first
and third compartment. The data were assumed to stem
from two different studies. The difference between the two
studies is nothing but the dosing type; in study one, the
dosing type was IV bolus, whereas in study two, the dosing
type was oral. A total of 50 individuals were simulated for
each study. A single dose was administered at time zero
and observations were taken at asymmetric timepoints. The
initial conditions of all compartments were set to zero and
the parameters of the model were estimated with NON-
MEM. The ODEs of the model are shown in Eqs. 1–4:
dy1
dt
52k10  y12k12  y11k21  y22k13  y11k31  y31ka  y4 (1)
dy2
dt
5k12  y12k21  y2 (2)
Figure 2 Optional input in MatVPC for model one. In this interface, the user can modify the default values of 40 characteristics of the
VPC and QVPC plots (for a detailed description of these features see Table 1). The VPC and QVPC plots shown in Figure 3 were
constructed using the input values shown in this figure.
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Figure 3 VPC and QVPC plots for model one. (a,d) VPC plots generated by MatVPC showing the results from compartment two and
study one (a) and two (d). (b,e) VPC plots generated by Xpose-PsN showing the results from compartment two and study one (b) and
two (e). Blue dots correspond to the observations. Red dashed lines correspond to the 5th and 95th percentiles of the observations,
whereas red solid lines correspond to the median of the observations. Black dashed lines correspond to the 5th and 95th percentiles
of the simulations, whereas black solid lines correspond to the median of the simulations. Blue shaded areas represent the 90% confi-
dence intervals of the simulation 5th and 95th percentiles, whereas pink shaded areas represent the 90% confidence intervals of the
simulation median. (c,f) QVPC plots of compartment two and study one (c) and two (f), as constructed by MatVPC. At each timepoint,
the black bar presents the observed data below the model predicted median (red dots), whereas the dark grey bar shows the observed
data above the model predicted median. The total of the black and grey bar combined presents the percentage of available data (here
100%). (g–i) The 200 Monte Carlo simulations of model one and study two (oral dosing) for compartment one (g), two (h), and three
(i). Green dashed lines correspond to the median of the 5th and 95th percentiles of the Monte Carlo simulations. Red lines correspond
to the median of the 50th percentile of the Monte Carlo simulations. Shaded areas represent the 90% prediction intervals of the Monte
Carlo simulation percentiles.
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dy3
dt
5k13  y12k31  y32k30  y3 (3)
dy4
dt
52ka  y4 (4)
To generate VPC and QVPC plots of model one using
MatVPC, the user is first required to open the MATLAB file
parameters and provide the model parameters therein.
Once the parameters have been provided, the user must
open the MATLAB file ODEs and type the Eqs. 1–4. A
snapshot of the parameters and the ODEs file upon insert-
ing all the pertinent information of model one is shown in
Figures 1a,b, respectively.
Upon completion of the above steps, the following com-
mand must be typed in the command window:
MatVPC(’obs.csv’,{’study’}). This command requests a
VPC that is based on the dataset called obs.csv and is
stratified by study. Once the user inserts this command
and presses “enter,” they are asked to provide the name
of the model and whether they want to simply create a
VPC from previously saved simulation results or to simu-
late new data and plot the VPCs. Following their response
(y/n), MatVPC opens a user-friendly interface with optional
input that bears default values. Figure 2 shows a snap-
shot of this interface, which includes the optional input
used for constructing VPC and QVPCs for model one.
After pressing “OK” at the bottom of the interface,
MatVPC runs all the required simulations, calculates the
respective percentiles, constructs the VPC and QVPC
plots, and saves them as MATLAB figures (.fig) in a folder
that is named after the model name. Unlike comparable
software, by saving the plots as MATLAB figures, MatVPC
allows for postprocessing of the plots. More specifically,
the user can open the figures (VPC, QVPC, or Monte
Carlo simulation plots) that are saved in .fig format and
interactively modify their characteristics, such as: (i) the
type, color, or size of the curves; (ii) the axes labels and
their font size; (iii) the figure title and its font size; (iv) the
size, shape, or resolution of the figure; and (v) the axes
limits. Modifying these characteristics can also be done
using the command line, but it is not recommended as it
is usually rather laborious. More details about this can be
found on MATLAB’s website (http://www.mathworks.com/
help/symbolic/edit-graphs. html?searchHighlight5edit).
As the sampling times in this case were asymmetric, we
exploited the automatic binning option of MatVPC to bin the
Figure 4 Required input in MatVPC for model two. (a) Input in file “parameters.” Please notice the extra term, “params(5),” that has
been added to the parameter list. (b) Input in file “ODEs.” Please note that “params(5)” has been added to Eq. dy(1) to account for IV
infusion dosing.
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data of model one (i.e., “yes” was selected in the “automatic
binning” option). The VPC and QVPC plots of model one as
generated by MatVPC are shown in Figure 3. VPC plots
of model one were also constructed with Xpose and
PsN (running the simulations in NONMEM and using the bin
edges calculated by MatVPC) and are also provided in
Figure 3. For simplicity, we only show the results from compart-
ment two of each study but the agreement between MatVPC
plots and Xpose plots was consistent for all compartments.
As discussed above, one of the key characteristics of
MatVPC is the option of performing Monte Carlo simulations
of a QSP model, either accounting for or neglecting the resid-
ual error. Here, we carried out Monte Carlo simulations of
model one (only for study two) without taking into considera-
tion the residual error. To do so, the RUV terms in the
“parameters” file were set equal to zero (see Supplemen-
tary Figure S1). In addition, in the optional input interface,
for “plot observations” was selected “no” and the “simulated
time beyond observations” was set equal to 0.2, as we were
interested in the dynamics of the model from time zero to
20% additional time beyond the timepoint of the latest obser-
vation (see Supplementary Figure S2). The results of the
simulations of the three compartments of study two (oral dos-
ing) are presented in Figure 3.
Figure 5 VPC and QVPC plots for model two. (a) VPC plots of compartment one generated by MatVPC. (b) VPC plots of compartment
one generated by Xpose-PsN. Blue dots correspond to the observations. Red dashed lines correspond to the 5th and 95th percentiles
of the observations whereas red solid lines correspond to the median of the observations. Black dashed lines correspond to the 5th
and 95th percentiles of the simulations, whereas black solid lines correspond to the median of the simulations. Blue shaded areas rep-
resent the 90% confidence intervals of the simulation 5th and 95th percentiles, whereas pink shaded areas represent the 90% confi-
dence intervals of the simulation median. (c) QVPC plots of compartment one as generated by MatVPC. At each timepoint, the black
bar presents the observed data below the model predicted median (red dots), whereas the dark grey bar shows the observed data
above the model predicted median. The total of the black and grey bar combined presents the percentage of available data (here
100%). (d) The 200 Monte Carlo simulations of model two for compartment one. Purple dashed lines correspond to the median of the
5th and 95th percentiles of the Monte Carlo simulations. Purple solid lines correspond to the median of the 50th percentile of the
Monte Carlo simulations. Red shaded areas represent the 90% prediction intervals of the Monte Carlo simulation percentiles.
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Model two: two-compartment PK model with multidose
IV infusion
The second model was adopted from a previously pub-
lished study41 and describes simulated PK data of a
drug administered via IV infusion. In this case, a total of
100 individuals were simulated with asymmetrically
sampled observations. The parameters of this nonlinear
PK model were estimated in NONMEM. The model con-
sists of Eqs. 5 and 6:
dy1
dt
52k10  y12k12  y11k21  y22
Vm  ðy1V1Þ
Km1
y1
V1
(5)
dy2
dt
5k12  y12k21  y2 (6)
It is important to note that in case IV infusion dosing is
simulated, an additional term should be added in the model
to account for IV infusion dosing. This term is simply
“params(n),” where “n” is equal to the number of model
parameters plus one (please note that all parameters are
inserted as “params(i)”); “params(n)” should invariably be:
(i) the last parameter listed in the file “parameters,”; (ii)
equated to zero; and (iii) added to the equation describing
the dynamics of the compartment in which IV dosing is
administered. In this example, the term “params(5)” was
added to Eq. 5 as the IV infusion is given in compartment
one (see file “parameters” and “ODEs” in Figure 4).
Similarly to model one, in order to generate the VPC and
QVPC plots of model two using MatVPC, the user must
open the MATLAB file “parameters” and insert the model
parameters. Once the parameters have been provided, the
user must open the MATLAB file “ODEs” and type the
ODEs shown in Eqs. 5 and 6, along with the additional
term that accounts for IV infusion dosing. A snapshot of the
completed MATLAB files “parameters” and “ODEs” file is
depicted in Figures 4a,b, respectively. Please note that in
file “parameters” an additional parameter, “params(5)50,”
has been listed. As shown in file “ODEs,” this parameter
has then been incorporated in the first ODE of the model
(see last term in first ODE).
Upon inserting this information in the two files, the user
should type in the command window the following:
“MatVPC(‘obs.csv’)”. MatVPC then asks the user to provide
the model name and to define whether they want to con-
struct VPC plots from scratch or to capitalize on previously
generated simulation data. Upon completing these steps, a
MATLAB interface with the optional input pops up. A
Figure 6 Required input in MatVPC for model three. (a) Input in file “parameters.” (b) Input in file “ODEs.” For a detailed description
about the input see caption in Figure 1.
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snapshot of this interface with the optional input used for
model two is shown in Supplementary Figure S3. Please
note that automatic data binning has been requested
through this interface as the sampling timepoints were not
consistent and manual binning of data would be challeng-
ing. After pressing “OK” at the bottom of this interface,
MatVPC undergoes all the necessary steps and constructs
the VPC and QVPC plots of model two. Figures 5a,c illus-
trate the VPC and QVPC plots, respectively, as constructed
by MatVPC. Figure 5b shows the VPC of model two as
generated with PsN and Xpose (with the simulations con-
ducted in NONMEM and using bin edges calculated by
MatVPC). For simplicity, only the plots from compartment
one are shown.
In addition to generating the VPC and QVPC plots of
model two, we also carried out 200 Monte Carlo simula-
tions and the results are presented in Figure 5d. The
“parameters” and “ODEs” files, along with the selected
options in MatVPC interface, that were used to generate
the Monte Carlo simulation plots are shown in Supplemen-
tary Figures S4 and S5, respectively.
Model three: PD model describing the time-course of
body weight
The third case example is a formerly presented highly nonlin-
ear PD model that describes the time-course of body weight.42
The simulated dataset includes observations from a total of
500 subjects that are involved in two different studies, 250
subjects belonging to study one and 250 subjects belonging to
study two. The difference between the two studies here is the
sampling times. The PD model is provided in Eq. 7:
dy1
dt
5kin2kout  y1  11DSTIM  kdekde2krel  ðe
2krel Time2e2kde TimeÞ  kde
 
(7)
whereby kin is the rate of weight gain, kout is the rate of weight
loss, kde and krel are associated with the onset and loss of the
lifestyle intervention effect and DSTIM is the maximum frac-
tional increase in kout caused by the lifestyle intervention. The
values of these parameters were estimated using Monolix.
The “parameters” and “ODEs” files that were utilized in
MatVPC to construct the VPC and QVPC plots of model
Figure 7 VPC and QVPC plots for model three. (a,d) VPC plots of study one (a) and study two (d) generated by MatVPC. (b,e) VPC
plots of study one (b) and study two (e) generated by Monolix. Blue dots correspond to the observations. Green lines correspond to
the 5th, 50th, and 95th percentiles of the observations. Black lines correspond to the 5th, 50th, and 95th percentiles of the simulations.
Light blue shaded areas represent the 90% confidence intervals of the simulation 5th and 95th percentiles whereas pink shaded areas
represent the 90% confidence intervals of the simulation median. (c,f) QVPC plots of study one (c) and two (f), as generated by
MatVPC. At each timepoint, the black bar presents the observed data below the model predicted median (red dots), whereas the dark
grey bar shows the observed data above the model predicted median. The total of the black and grey bar combined presents the per-
centage of available data (here 100%).
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three are shown in Figures 6a,b, respectively. As the data
originate from two distinct studies, the user would need to
stratify on the study number. To do so, the following
should be typed in the command window: “MatVPC
(’obs.csv’,{’study’}).” This command requests VPC and
QVPC plots of the PD model shown in Eq. 7, using the data-
set called “obs.csv” while stratifying on the variable “study.”
Once the user defines the name of the model, and whether
they want to use previous simulation results, the MatVPC
interface with the optional input appears. The optional input
used in the construction of VPCs for model three is provided
in Supplementary Figure S6. Upon pressing “OK” in this
interface, the VPCs and QVPCs of the model are generated
and saved. These VPC and QVPC plots are illustrated in
Figure 7. The respective VPC plots were also generated
with Monolix and are provided in Figures 7b,e. It should be
underlined that the automatic binning approach implemented
in MatVPC and Monolix is identical.9,40
DISCUSSION
We have presented a MATLAB-based tool, dubbed MatVPC,
that simulates and generates VPC and QVPC plots of QSP
models. The plots generated by MatVPC were compared with
plots constructed by the gold standard tools in the pharmaco-
metrics community, PsN (with NONMEM) and Monolix,43 and
the results were interchangeable across all case studies.
Despite its flexibility, MatVPC does have its drawbacks.
At present, MatVPC generates QVPC plots using only the
available data and does not account for missing data.11 In
addition, it can currently run only on a single computer and
is not designed for running in parallel processors. However,
MatVPC will be continuously advanced and its future ver-
sions will address these imperfections.
MatVPC is publicly available and can be utilized by users
with little or no prior MATLAB experience. This computational
tool can be potentially expanded to perform key analyses in
systems pharmacology,44 such as sensitivity analysis45 or
model reduction.38,46 Collectively, MatVPC constitutes a use-
ful addition to the openly available toolboxes exploited by
quantitative as well as clinical pharmacologists.
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